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The beneficial effects of green tea polyphenols (GTP) against metabolic syndrome and type 2 diabetes by suppressing appetite and
nutrient absorption have been well reported. However the direct effects and mechanisms of GTP on glucose and lipid metabolism
remain to be elucidated. Since the liver is an important organ involved in glucose and lipid metabolism, we examined the effects
and mechanisms of GTP on glycogen synthesis and lipogenesis in HepG2 cells. Concentrations of GTP containing 68% naturally
occurring (−)-epigallocatechin-3-gallate (EGCG) were incubated in HepG2 cells with high glucose (30mM) under 100 nM of
insulin stimulation for 24 h. GTP enhanced glycogen synthesis in a dose-dependentmanner. 10𝜇Mof EGCG significantly increased
glycogen synthesis by 2fold (𝑃 < 0.05) compared with insulin alone. Western blotting revealed that phosphorylation of Ser9
glycogen synthase kinase 3𝛽 and Ser641 glycogen synthase was significantly increased in GTP-treated HepG2 cells compared with
nontreated cells. 10𝜇M of EGCG also significantly inhibited lipogenesis (𝑃 < 0.01). We further demonstrated that this mechanism
involves enhanced expression of phosphorylated AMP-activated protein kinase 𝛼 and acetyl-CoA carboxylase in HepG2 cells. Our
results showed that GTP is capable of enhancing insulin-mediated glucose and lipid metabolism by regulating enzymes involved
in glycogen synthesis and lipogenesis.
1. Introduction
Metabolic syndrome is a complex cluster of several metabolic
abnormalities that significantly increases the risk of cardio-
vascular disease and the onset of type 2 diabetes (T2D).
Metabolic syndrome has become a significant public health
problem, affecting millions of people all over the world
[1]. Treatment of metabolic syndrome is crucial to public
health. It involves improving underlying insulin resistance
and central obesity in individuals through oral medications
and lifestyle modifications [2] such as increasing physical
activity and promoting healthy diets. If left unresolved in an
individual, metabolic syndrome may progress to T2D and
cardiovascular morbidity.
After water, tea is the most widely consumed beverage
in the world. Consumption of green tea (Camellia sinensis,
Theaceae) in particular is reported to have various beneficial
effects on metabolic syndrome. One such example of the
beneficial effects of green tea consumption is its role in
promoting fat oxidation, which is a key preventative of
obesity in healthy individuals [3]. Another example of the
benefits of green tea consumption is its observed effect in
reducing the occurrence of T2D in both laboratory animal
studies [4, 5] and clinical studies involving subjects with
metabolic syndrome or prediabetes [6, 7] by improving
insulin sensitivity and glucose tolerance.
Several lines of studies suggest that the antidiabetic effects
of green tea consumption are probably due to the effect
of green tea (or more specifically, its active ingredients) in
lowering central obesity—a major component of metabolic
syndrome—by suppressing appetite and nutrient absorption
[8, 9]. Yang et al. and Muramatsu et al. [10, 11] report that
polyphenolic compounds found in green tea extract such
as (−)-epigallocatechin-3-gallate (EGCG) increase fecal lipid
content in high fat-fed rats. EGCG has also been shown to
increase fecal cholesterol excretion and fecal fat excretion in
high fat, high cholesterol-fed rats when compared with the
control group [9]. Considerable amount of data demonstrate
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Figure 1: Structures for four polyphenols in green tea.
that one mechanism by which tea polyphenols act against
obesity and hyperlipidemia is by modifying dietary fat
emulsification in the gastrointestinal tract and inhibiting of
gastrointestinal lipolysis [12, 13].However, it has been recently
observed that polyphenols in green tea are also capable of
accessing the bloodstream through the intestinal epithelial
outer cell membrane [14]. Due to a lack of study on this
observation, questions remain as to the effect of any direct
actions andmechanisms of green tea consumption on glucose
and lipid metabolisms in insulin-targeted tissues and organs.
The liver is a major organ involved in glucose and
lipid metabolism. Insulin resistance in the liver leads to
increased hepatic glucose production and lipogenesis, which
contributes to hyperglycemia and lipotoxicity-induced pan-
creatic 𝛽-cell dysfunction [15]. To understand the direct
effects and mechanisms of green tea polyphenols (GTP) on
regulating glucose and lipidmetabolism in the liver, we exam-
ined the dose-response effect of GTP on glycogen synthesis
and lipogenesis in human hepatoma HepG2 cells. HepG2
cells are considered suitable cellular models for examining
glycogen synthesis and lipogenesis in the liver [16].
2. Materials and Methods
2.1. Green Tea Polyphenols and (−)-Epigallocatechin-3-Gallate.
The tea polyphenols (99% purity) were extracted from
green tea leaves grown in Guizhou province, South-Western
China, by Zuyi Lushen Kangyuan Co (Guizhou, Meitan,
China). The polyphenolic compounds identified using liq-
uid chromatography-mass spectrometry (LC-MS) were 68%
EGCG, 7% epigallocatechin (EGC), 1% epicatechin gallate
(ECG), and 19% epicatechin (EC) in GTP (w/w), the struc-
tures of these polyphenols are shown in Figure 1. According
to the literature, the most potent bioactive catechin in GTP
is EGCG, followed by ECG, and EGC and EC with weak
biological action [17]. To observe dose-response relationship
of GTP on glycogen synthesis and lipogenesis, the molecular
weight of EGCG was used to calculate a series of mole
concentrations (0.01, 0.1, 1, and 10𝜇M) to present the total
GTP (1 : 0.68 GTP versus EGCG) for the cellular study
mentioned later and the term of GTP-EGCG was used to
present all results from total polyphenols used in this study.
2.2. Cell Culture and Treatment. Human hepatoma HepG2
cells (ATCC HB 8065, ATCC, VA, USA) were maintained
in Dulbecco’s modified eagle medium (DMEM) containing
normal glucose (5mM glucose), supplemented with 10%
fetal bovine serum (FBS), and 100U/mL penicillin (GIBCO,
Aukland, NZ) in an incubator (37∘C and 5% CO
2
). HepG2
cells were grown in complete media (CM) with 10% FBS
until 70% cell confluence was reached. 24 h prior to all
experimental procedures, appropriate glucose concentrations
(5mM or 30mM D-glucose) were added to cells.
Approximately 4 × 103 cells were seeded to 24-well plates
for all assays. When confluent, CM was discarded and then
starvingmedium (SM) containing 0.5% FBSwas added. After
6 h incubation with SM, 100 nM of insulin (Eli Lilly Pty
Ltd, NSW, Australia) was added in each well, followed by
adding a range of 0.01–10 𝜇M EGCG into appropriate wells
in duplicates. Plates were maintained for 24 h in 5% CO
2
at
37∘C. This treatment procedure was used for all experiments
in this study.
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2.3. Measurement of Insulin-Stimulated Glycogen Synthesis.
HepG2 cells administered normal (5mMD-glucose) or high
glucose (30mM D-glucose) were used to determine the
effect of GTP on 14C-glucose incorporation into glycogen.
1 𝜇Ci 14C-glucose solution was added to GTP-treated HepG2
cells for 30min at 37∘C. The reaction was stopped with
30% KOH and transferred into falcon tubes. 30% KOH
with 6mg/mL glycogen was added, and tubes were vortexed
carefully and placed on a heating block set at 100∘C for
15min and turned down to 85∘C for a further 15min. 95%
ethanol was added to all tubes and vortexed gently until the
samples turned uniformly cloudy. Tubes were returned to
85∘C heating block for 30min then into an ice bath. Tubes
were left to chill for 15min to completely precipitate the
glycogen. Samples were centrifuged at 2,800×g at 4∘C for
10min to pellet glycogen and then ethanol was aspirated, and
samples in deionised water were transferred to scintillation
vials containing 5mL scintillation liquid. The samples were
counted using a scintillation counter (PerkinElmer Inc, MA,
USA). Glycogen synthesis were attained by measuring the
rate of incorporation of D-[U-14C]glucose into glycogen.
2.4. Lipogenesis Assay and Oil Red O Staining. The effect
of GTP on lipogenesis in HepG2 cells was tested by a
colorimetric assay (Cayman Chemical Company, MI, USA),
as previously described [18]. Following standard treatment
of HepG2 cells with GTP on coverslips in 24-well plates,
SM was removed from the wells with a pipette for staining.
75 𝜇L of Lipid Droplets Assay Fixative (Cayman Chemical
Company,MI,USA)was added to eachwell and incubated for
15min.Wells were washed with wash solution twice for 5min
each and left to dry completely by placing the plate under a
blowing hood. Dye extraction solution was added and wells
were gently mixed for 20min, and the degree of lipogenesis
was quantified from lipid droplets in cells by obtaining
the absorbance at 490 nm single fixed wavelength with a
microplate reader (Bio-Tek Instruments Inc., VT, USA).
In the separate cell cultures, Oil Red O working solution
(Sigma-Aldrich, St. Louis, MO, USA) was added to all wells
including the background wells containing no cells and
incubated for 20min. Wells were washed with distilled water
several times until the water appeared to be clear (until
any pink was not visible). At this point, microscopic images
were taken to visualize pink/red oil droplets staining in
differentiated cells with the Olympus microscope and an
Olympus digital camera (DP70, Tokyo, Japan) using Image-
Pro6.2 software (Media Cybernetics, Inc. MD).
2.5. Western Blotting. After treatment with GTP-EGCG for
24 h, HepG2 cells were collected and homogenized using
RIPA buffer with protease inhibitors (Roche Diagnostics
Corporation, IN,USA), and lysateswere centrifuged at 14,000
×g for 20min at 4∘C. Supernatants were collected and protein
concentrations were quantified using the Bradford reagent.
HepG2 lysates were subjected to 7.5% SDS-polyacryl-
amide gel electrophoresis then transferred to 0.45 𝜇M
polyvinyldene difluoride (PVDF) membrane and immun-
oblotted with primary antibodies phospho-GSK3𝛽 (Ser9),
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Figure 2: Glycogen synthesis in response to GTP-EGCG treatments
in HepG2 cells.The cells were pretreated with high glucose (30mM)
for 24 h then incubated with various concentrations of EGCG (0.1–
10𝜇M) with 100 nM insulin for 24 h. HepG2 cultured with high
glucose without insulin was used to confirm that the HepG2 cells
became insulin resistant. 1 𝜇Ci 14C-glucose solution was added
to HepG2 cells for 30min at 37∘C. The results were attained
by measuring the rate of incorporation of D-[U-14C]glucose into
glycogen. Data are means ± S.E. The data are from five separate
experiments. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with insulin
stimulation alone.
GSK3𝛽, phospho-GS (Ser641), GS, phospho-AMPK𝛼
(Thr172), AMPK𝛼, phospho-ACC (Ser79), ACC (Cell
Signaling Technology Inc, MA, USA), and 𝛽-actin (Santa
Cruz, CA, USA) at 1 : 1000 dilution and secondary antibodies
(Santa Cruz, CA, USA) at 1 : 10000 dilution. Blots were then
developed with enhanced chemiluminescence (ECL) (Pierce,
IL, USA) according to manufacturer’s instructions. The
protein bands were visualized by ChemiDoc XRS systems
(Bio-Rad Laboratories, CA, USA) and Quality One 4.6.1
(Biorad) software and density of bands were quantified with
the same analysis program.
2.6. Statistical Analysis. Data are presented as the means ±
S.E. Comparisons across the variety of treatments were done
using one-way ANOVA followed by post-hoc analysis of
Tukey’s test to determine significant differences between the
two treatments using Prism version 4 (GraphPad Software
Inc, CA, USA). 𝑃 value < 0.05 was considered statistically
significant.
3. Results
3.1. GTP-EGCG Increased Glycogen Synthesis in HepG2 Cells.
To determine effect of GTP-EGCG on glycogen synthesis,
we measured 14C-glucose incorporation into glycogen in
HepG2 cells pretreated with high glucose (30mM). Our
previous study on cell viability with concentrations of EGCG
(0.01–10 𝜇M) showed that EGCG did not exert toxicity in
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Figure 3: Effects of dose response to GTP-EGCG on lipogenesis in HepG2 cells. HepG2 cells were stained with oil Red O solution, and the
dye was extracted from lipid droplets from cells. Images of cells were captured by microscope at 20x original magnification showing lipid
accumulation in cells stained by Oil Red O. (A) HepG2 cells cultured in 30mM glucose, (B) HepG2 cells cultured in 30mM glucose with
100 nM insulin stimulation, and (C) HepG2 cells cultured in 30mM glucose with 100 nM insulin stimulation and 10 𝜇M of GTP/EGCG.The
degree of lipogenesis was quantified from lipid droplets in cells by measuring the absorbance at 490 nm.The changes of lipogenesis by EGCG
treatments were calculated as the percentage of insulin stimulation alone. Data aremeans± S.E from five independent experiments. ∗𝑃 < 0.05
and ∗𝑃 < 0.01 compared with insulin treatment alone.
cells (data not shown). Under 100 nM insulin stimulation,
glycogen synthesis increased only 2% compared with HepG2
cells cultured with high glucose alone, indicating that high
glucose treatment induced insulin resistance in HepG2 cells.
Glycogen synthesis was enhanced by 41% and 53% (𝑃 < 0.05)
with 0.1 and 1𝜇M EGCG. 10 𝜇M of EGCG resulted in a 2fold
increase (𝑃 < 0.01) inHepG2.These data indicate that EGCG
increased glycogen synthesis in a dose-dependent manner
(Figure 2).
3.2. Lipogenesis Was Reduced in GTP-EGCG-Treated HepG2
Cells. Hepatic lipogenesis is the process bywhich acetyl-CoA
carboxylase (ACC) is converted to fats and involves subpro-
cesses of fatty acid synthesis and subsequent triglyceride (TG)
synthesis in the liver. Increased liver fat and elevated hepatic
lipogenesis have been demonstrated in obesity and insulin
resistance status. To observe effect of GTP-EGCG on lipid
deposition, Oil red O staining was used to view lipid droplets
in HepG2 cells cultured in high glucose (30mM) with
different treatments. Figure 3(a) showed a slight decrease in
lipid content in the cell culture with 100 nM insulin and
a visibly greater reduction of lipid droplets in HepG2 cells
treated with 100 nM insulin and 10𝜇M EGCG. To quantify
de novo lipid synthesis, HepG2 cells exposed to high glucose
were used to determine hepatic lipogenesis with different
treatment. At the presence of 100 nM insulin, lipogenesis
was reduced by 18% in high glucose treated HepG2 cells but
the statistically significant difference was not achieved. GTP-
EGCG treatments (0.1, 1 and 10 𝜇M) significantly inhibited
lipogenesis in HepG2 cells by 31%, 39% (both 𝑃 < 0.05),
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Figure 4: Effects of GTP-EGCG on expressions of phospho-GSK3𝛽 (Ser9) and phospho-GS (Ser641) in HepG2 cells. The cell lysates were
separated on 7.5% SDS-PAGE and incubated with antibodies against phospho-GSK3𝛽 (Ser9), GSK3𝛽, phospho-GS (Ser641), and GS as
described. 𝛽-actin was used as a loading control. A representative western blot of phosphorylation of GSK3𝛽 and GS from 5 independent
experiments is shown. Quantitative data are expressed as mean ± S.E. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with insulin-stimulated HepG2
cells with 30mM glucose and ##𝑃 < 0.01 compared with HepG2 cells with 5mM glucose.
and 65% (𝑃 < 0.01), respectively, compared with HepG2 cells
treatedwith insulin alone (Figure 3(b)).These results indicate
that GTP-EGCG improved insulin-medicated lipogenesis in
the hepatocytes.
3.3. GTP-EGCG Enhanced Hepatic Glycogen Synthesis by
Increasing Phosphorylation of Ser9 GSK3𝛽 and Ser641 GS
in HepG2 Cells. Insulin plays an important role in hepatic
glycogen synthesis and in insulin-resistant cellular models;
hepatic glycogen synthesis is markedly inhibited [19]. Glyco-
gen synthase kinase 3𝛽 (GSK3𝛽) is a rate-limiting enzyme,
which acts as a downstream regulatory switch for numerous
signaling pathways such as insulin action, hepatic glyco-
gen synthesis, and lipogenesis. Phosphorylation of GSK3𝛽
not only activates target enzymes of the insulin-signaling
pathway [20] but also regulates hepatic glycogen synthesis
by increasing glycogen synthase (GS) expression. Figures
4(a) and 4(b) showed that expression of phospho-GSK3𝛽
(Ser79) was significantly reduced in high glucose (30mM)
cultured HepG2 cells compared to HepG2 cells with normal
glucose (5mM). Expression of phospho-GS (Ser641) was also
impeded by 23%with 30mM glucose (Figures 4(a) and 4(c)).
Under 100 nM insulin stimulation, reduction of phos-
phorylation of GSK3𝛽 in high glucose treated HepG2 cells
was improved, and expression of phospho-GSK3𝛽 (Ser9) was
further enhanced by almost 2fold by EGCG (𝑃 < 0.01)
in HepG2 cells with 10 𝜇M EGCG treatment. A significant
enhancement of expression of phospho-GS (Ser461) was also
observed in EGCG treatedHepG2 cells, but insulin alone had
no effect on expression of phospho-GS (Ser461) (Figures 4(a)
and 4(c)).
3.4. GTP-EGCG Inhibited Insulin-Mediated Lipogenesis
through Increasing Phosphorylation of Thr172 AMPK𝛼 and
Ser79 ACC in HepG2 Cells. To understand the mechanism
of GTP on insulin-mediated hepatic lipogenesis, the effect
of 10 𝜇M EGCG on expressions of phosphorylated AMP-
activated protein kinase 𝛼 (AMPK𝛼) and ACC (two key
enzymes involved in hepatic lipogenesis) in HepG2 cells
exposed to 30mMglucose for 24 hwas analyzedwithwestern
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Figure 5: Effects of GTP-EGCG on expressions of phospho-AMPK𝛼 (Thr172) and phospho-ACC (Ser79) in HepG2 cells. Cell lysates were
separated on 7.5% SDS-PAGE and incubated with 1 : 1000 phospho-AMPK𝛼 (Thr172), AMPK𝛼, phospho-ACC (Ser79), and ACC (Cell
Signaling Technology Inc, USA)𝛽-actin was used as a loading control. A representative western blot analysis from 5 independent experiments
is shown (a). Data ((b) and (c)) are expressed as mean ± S.E. (𝑛 = 5), ∗𝑃 < 0.05, compared with HepG2 cells with 30mM glucose.
blotting. We found that expressions of phospho-AMPK𝛼
(Thr172) and phospho-ACC (Ser79) in high-glucose cultured
HepG2 cells were decreased when compared with normal
glucose cultures (data not shown). Exposure of 100 nM
insulin or 10 𝜇M EGCG alone did not change expressions
of phospho-AMPK𝛼 (Thr172) and phospho-ACC (Ser79).
Interestingly, expressions of phospho-AMPK𝛼 (Thr172) and
phospho-ACC (Ser79) were significantly increased when
HepG2 cells were treated with 100 nM insulin and 10 𝜇M of
EGCG (Figure 5), indicating a synergetic effect of EGCG and
insulin on phospho-AMPK𝛼 (Thr172) and phospho-ACC
(Ser79) expressions.
4. Discussion
In vivo studies have postulated that polyphenolic com-
pounds in green tea reduce body weight, prevent metabolic
syndrome, and fatty liver disease through blocking lipid
absorption [6–8]. To understand direct effects of GTP and
its major active compounds on glucose and lipidmetabolism,
we determined insulin-mediated glycogen synthesis and de
novo lipogenesis in HepG2 cells. HepG2 cells were firstly
exposed to high glucose to induce insulin resistance, and this
was shown by reduced insulin-stimulated glycogen synthesis
and elevated lipogenesis. EGCG, the most abundant and
potent active compound in GTP [17], was used to calculate
a series of mole concentrations to present the total GTP,
but the overall results of this study were from total GTP. In
this study, we observed dose-response relationship of GTP-
EGCG on glycogen synthesis and lipogenesis. 10 𝜇M EGCG
under 100mM insulin-stimulation significantly increased
rate of glucose incorporation into glycogen by a 2fold
increase in HepG2 cells. Our study also demonstrated that
at presence of 10 𝜇M of EGCG, the elevated lipogenesis
were normalized in insulin-resistant HepG2 cells. These
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findings indicate the beneficial effects of GTP-EGCG against
metabolic syndrome and diabetes is not only secondary to
inhibiting lipid absorption or antioxidant actions [21] but also
through its direct action to enhance glycogen synthesis and
decrease lipogenesis in insulin-targeted tissues.
Liver is a major organ involved in insulin-mediated
glucose and lipid metabolism. Under insulin-resistant state,
hepatic glycogen synthesis is diminished and is also associ-
atedwith increased lipogenesis, which leads to hyperglycemia
and contribute to the development of T2D [22]. In this study,
high-glucose culturedHepG2 cells were used tomimic a hep-
atic insulin-resistant state. The treatments with GTP-EGCG
ameliorated the diminished glycogen synthesis indicate that
GTP-EGCG is capable of controlling hyperglycemia through
reduction of hepatic glucose production.
To understand the molecular mechanism of GTP-EGCG
enhancement of glycogen synthesis, we have detected expres-
sions of phospho-GSK3𝛽 (Ser9) and phospho-GS (Ser641).
GSK3 is a rate-limiting enzyme which acts as a down-
stream regulatory switch for inactivation of GS leading
to reduction of glycogen synthesis [22, 23]. Insulin pro-
motes glycogen synthesis through enhancing expressions of
phospho-GSK3𝛽 (Ser9) and phospho-GS (Ser641). Treat-
ment with GTP/EGCG enhances phospho-GSK3𝛽, which
mimics insulin’s inhibitory effects on GSK3𝛽, enhances activ-
ity of GS, and subsequently increased glycogen synthesis in
HepG2 cells.
Moreover, GTP-EGCG treatment significantly increased
phospho-AMPK𝛼 (Thr172) and phospho-ACC (Ser79)
expressions in HepG2 cells. AMPK and ACC are key
enzymes that regulate lipogenesis in the liver [24] and
contribute significantly to overall metabolism of lipids.
Insulin activates AMPK by promoting its phosphorylation
at Thr172 [24] and by direct activation via an allosteric
AMP site. Evidence shows that phosphorylation of Thr172,
the major stimulatory phosphorylation site of 𝛼 subunit, is
essential for AMPK activity [25]. An increase in AMPK𝛼
phosphorylation in the liver leads to phosphorylation and
inactivation of ACC resulting in decreased lipid synthesis,
through the biosynthesis of malonyl-CoA from acetyl-CoA,
and this may lead to decreased lipid synthesis and regulation
of fatty acid oxidation [26].
5. Conclusion
We found that GTP-EGCG has direct effects on regulation of
glucose and lipid metabolism in high-glucose treated HepG2
cells. Results demonstrate that hepatic glycogen synthesis was
significantly upregulated in HepG2 cells with GTP-EGCG
treatment through increased phosphorylation of GSK3𝛽 and
GS, which are critical elements in the regulation of hepatic
glycogen synthesis in vivo. GTP also inhibited hepatic lipo-
genesis in cells through increased expressions of phospho-
AMPK𝛼 (Thr 172) and phospho-ACC (Ser79).
In conclusion, our findings showed the beneficial effects
of GTP against metabolic syndrome and diabetes through
direct enhancement of glycogen synthesis in the liver and
decreased hepatic lipogenesis.
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